Last updated: August 17, 2026

Examiner: HOWARD, ZACHARY C

Tech Center 1600 • Art Units: 1646 1674

This examiner grants 64% of resolved cases

Performance Statistics

63.8%

Allow Rate

+3.8% vs TC avg

1,007

Total Applications

+38.0%

Interview Lift

1032

Avg Prosecution Days

Based on 957 resolved cases, 2023–2026

5.0%

§101 Eligibility

22.9%

§102 Novelty

18.3%

§103 Obviousness

37.5%

§112 Clarity

App #	Title	Status	Assignee
18015444	METHODS FOR TREATING CARDIOVASCULAR DISEASE	Final Rejection	Novo Nordisk A/S
18031840	CD47 BLOCKADE AND COMBINATION THERAPIES THEREOF FOR REDUCTION OF VASCULAR INFLAMMATION	Non-Final OA	The Board of Trustees of the Leland Stanford Junior University
18252005	METHODS AND SYSTEMS FOR CLASSIFICATION AND TREATMENT OF SMALL CELL LUNG CANCER	Non-Final OA	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17849793	ANTI-C5A ANTIBODIES	Non-Final OA	Alexion Pharmaceuticals, Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.